I-rhinitis ye- allergen ingenye yezimo zezokwelapha ezingavamile kakhulu, ezithinta abantu abangu-30-40%, eziguqula zibe ngamakhulu ezigidi zabantu emhlabeni jikelele. Izimpawu ze-rhinitis ye-allergen zihlanganisa ukungqubuzana komswakama, ukugcoba emanzini, impumu egijimayo, ukukloloda, ukuhlobisa iso, ukuhogela komphimbo kanye nokudonsa umzimba ngemuva. I-rhinitis ye-allergen ibangelwa yizifo eziphefumulayo, ezifana ne-pollens, izibunji , i-dander yezilwane, kanye no-dust mite nama-particroach particles.
Kunezinhlobo zokwelashwa eziningana ze- rhinitis ye-allergen , ukufaka izinyathelo zokugwema , imithi kanye ne- allergen immunotherapy . Ukugwema izifo ezithile, ezifana ne-pollen evulekile emoyeni kanye nesikhunta, noma kunjalo, kunzima, uma kungenakwenzeka.
Kuyini Isihlungi Sezilwane Zomzimba?
Izihlungi ze-Nasal zisanda kuhanjiswa njengendlela yokuvimbela izifo ezivame ukungena emoyeni ukuze zifinyelele emagqumeni amancane emphunzini, okuyilapho ukuphendula okwenziwe khona kuvela khona. Isihlungi semisipha senzelwe ukulingana ngaphakathi ngaphakathi kwesikhumba futhi senze izihlungi zokuhlunga ezivela emoyeni ophefumulayo. Ngokusobala, ukuze isihlungi semisipha sibe yindlela yokwelapha ephumelelayo ekuvimbeleni izimpawu ze-rhinitis eziqhekekile, kuzodingeka ukuthi zikhululeke ukugqoka umsebenzisi, futhi cishe zingabonakali uma zigugile. Idivayisi izophinde idingeke iphumelele ekuvimbeleni izimpawu ze-rhinitis ye-allergen.
Ingabe Izihlungi Zezifo Zokungcola Zisebenza?
Ucwaningo lwamuva, olwanyatheliswa ngo-2014, lwalufuna ukucacisa ukusebenza komcibisholo womzimba, okuthiwa i-Rhinix, ekuvimbeleni izimpawu zokungenwa kwemvelo ezibangelwa ukutholakala kwempova ephuma emoyeni.
Izisebenzi zokuvolontiya ezingama-20 ezinomlando wobuntshani obusotshani babonakala emvoleni utshani endaweni yendawo yokuhlanza indawo (EEU) phakathi nezinyanga zasebusika - ukuze uqiniseke ukuthi kwakungekho ukungcola kwemvelo yemifino engafaka imiphumela. I-EEU iyindlela ehlelekile yokwethula izisebenzi zokuzithandela ezifundelwa emkhakheni othile we-impova ngokuthi abalandeli badonsa inani elithile lempova elizungeze ikamelo.
Kulesi sifundo, amavolontiya agqoka noma idivayisi yangempela ye-Rhinix ehlunga i-pollen, noma idivayisi ye-placebo engenayo isihlungi, futhi yavezwa emvoleni utshani ku-EEU imizuzu engu-210. Amavolontiya abike izimpawu ezehlukene ekuqaleni (ngaphambi kokungena e-EEU) njalo ngemizuzu engama-30 ngesikhathi sokutholakala kwe-pollen, bese-ke emva kwamahora amathathu emva kokuphuma kwe-EEU.
Imiphumela yocwaningo yayingxubekile. Ngokuvamile, lapho kuboniswa izimpawu eziphelele, kwakungekho umehluko phakathi kwamavolontiya agqoke i-Rhinix uma kuqhathaniswa ne-devicebo filter device. Idivayisi ye-Rhinix yayiphumelele ekunciphiseni ezinye izimpawu zokugula eziqhathaniswa ne-placebo, noma kunjalo, kufaka phakathi ukushaywa kwe-nasal, ukunyakaza, nokuphunga komphimbo. Ngezinye izimpawu zokugula, njengephunga eligijima kanye nokungqubuzana kwe-nasal, idivayisi ye-Rhinix ayikhombisi inzuzo phezu kwecebo lokuhlunga le-placebo. U-Rhinix wayephephile ngokuphelele ukusebenzisa, wayebekezelela kahle futhi akazange abange nemiphumela emibi kakhulu.
Indlela Ehlukile Yokuthola Imishanguzo Yezokwelapha
Idivaysi yokuhlunga emiseleni eyenza ukuvimbela impova, futhi mhlawumbe ezinye izifo ezivuthayo ezifakwe emoyeni ezinjenge-pet dander nenkuni, kubonakala sengathi ziwusizo ekunciphiseni noma ekuvimbeleni ezinye izinhlobo zezimpawu zomzimba ezingezansi. Ngenkathi isihlungi semisipha singase singavimbeli ngokuphelele izimpawu zokungezwani komzimba okwenzeka, kubekezelela kahle, kalula futhi kube nzima kwabanye abantu ukubona, futhi kungabangeli nemiphumela emibi kakhulu.
Ngomuntu okhathazekile ngokuthatha imithi yokwelapha i-rhinitis ye-allergen, futhi akayena omele ukhetho lwe-allergen immunotherapy, isihlungi sokungalingani komzimba singase sibe yilokho odokotela abaya khona.
> Umthombo:
> Kenney P, Hilberg O, Pedersen H, Nielsen OB, Sigsgaard T, et al. Izihlungi ze-Nasal ze-Treatment of Rhinitis ye-allergen: I-Trial-Double Blind, i-Placebo-Controlled Crossover Clinical Trial. J Allergy Clin Immunol. 2014; 133: 1477-80.